Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, May 2009, p. 2158-2159, Vol. 53, No. 5
0066-4804/09/$08.00+0 doi:10.1128/AAC.01563-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Department of Pediatrics, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China,1 Wuxi Research Institute of Genetics & Cloning Technology, Wuxi, Jiangsu 214026, China,2 Department of Pediatrics, Central Hospital of China National Petroleum Corporation, Langfang, Hebei 065000, China3
Received 24 November 2008/ Returned for modification 22 December 2008/ Accepted 22 February 2009
|
|
|---|
|
|
|---|
Throat swab specimens were collected from 300 inpatient and 70 outpatient children with respiratory tract infection at the Pediatric Department of Beijing Friendship Hospital, affiliated with Capital Medical University, during June 2003 to June 2006. Modified Hayflick medium was used for the isolation and growth of M. pneumoniae. Nested PCR was carried out to verify the identity of M. pneumoniae, using primers which amplify part of the 16S rRNA gene as described previously (2). The MICs of erythromycin, azithromycin, and josamycin required to inhibit M. pneumoniae growth were determined by the microdilution method (1). A reference strain, FH, was used as a drug-sensitive control. Erythromycin resistance was defined as having a MIC of
32 µg/ml in accordance with the 2006 standards recommended by the CLSI (formerly NCCLS). To examine the molecular mechanisms of drug resistance, the 23S rRNA gene was amplified by nested PCR and the product was sequenced as described previously (8). The DNA sequences were compared with the sequence of M. pneumoniae M129 (GenBank accession no. X68422).
Fifty clinical M. pneumoniae strains (44 of them from inpatients) were isolated from the 370 specimens collected. Four strains were susceptible to macrolides, and the other 46 (92%) strains were macrolide resistant. MICs of resistant strains to erythromycin, azithromycin, and josamycin were higher than that of the reference strain and higher than the CLSI guidelines (especially in the case of erythromycin and azithromycin). Table 1 shows the MIC range, MIC50, and MIC90 of clinical isolate strains and the M. pneumoniae reference strain.
|
View this table: [in a new window] |
TABLE 1. MIC range, MIC50, and MIC90 of clinical isolate strains and the M. pneumoniae reference strain
|
M. pneumoniae is a common pathogen associated with respiratory tract infection in children and teenagers, and macrolides are the first choice for treatment. Since their first introduction, increasing use of macrolides has given rise to increasing resistance among bacteria, but the sensitivity of M. pneumoniae to these drugs was unclear. In recent years, drug-resistant M. pneumoniae strains have been isolated from patients in a number of locations. In Japan, macrolide-resistant strains have been reported by Morozumi (3) and Matsuoka (1). In March 2005, D. Xin reported four of five M. pneumoniae strains were resistant to erythromycin in China (7, 8). Pereyre reported two macrolide-resistant strains in France (5), and Wolff reported five macrolide-resistant strains isolated in America (6). In these and our own studies, mutations at position 2063 or 2064 in domain V in the 23S rRNA gene were shown to be the predominant mutations associated with resistance.
The 44 inpatients who produced macrolide-resistant samples showed positive M. pneumoniae immunoglobulin M antibody tests around the 8th to 14th day of the illness and were diagnosed clinically as being infected with M. pneumoniae (including four cases which were complicated with pleural effusion). All of the patients had had prior treatment with macrolides before hospitalization. In this study, most of the isolates cultured were shown to be macrolide resistant in vitro and it was not possible to determine whether macrolides would have been effective in vivo. Furthermore, there were no patients infected with susceptible strains to act as a control. Further research will be needed to determine whether macrolides retain any clinical efficacy in patients shown to be harboring strains of M. pneumoniae which may be defined in vitro as macrolide resistant.
Published ahead of print on 9 March 2009. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»